The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival impact of KRAS mutation in metastatic colorectal cancer (mCCR) under first-line treatment.
 
Maria Cecilia Mathias
No Relationships to Disclose
 
Felippe Lazar Neto
No Relationships to Disclose
 
Mariana Carvalho Gouveia
No Relationships to Disclose
 
Lucas Stangler
No Relationships to Disclose
 
Mateus Zapparoli Claro
No Relationships to Disclose
 
Evandro Sobroza de Mello
No Relationships to Disclose
 
Jorge Sabbaga
No Relationships to Disclose
 
Maria Ignez Braghiroli
Honoraria - Amgen; Bayer; BMS Brazil; Eurofarma; MSD; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; Johnson & Johnson/MedTech; Lilly; Merck; MSD; Roche; SERVIER; SERVIER
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb Brazil (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bayer; BMS Brazil; MSD; SERVIER
 
Camila M Venchiarutti Moniz
Honoraria - Libbs
Research Funding - BMS; Immix BioPharma; Jazz Pharmaceuticals; Merck; Servier/Pfizer; Takeda
Travel, Accommodations, Expenses - Libbs; Merck
 
Paulo Marcelo Hoff
Leadership - Oncologia D’Or
Stock and Other Ownership Interests - Oncostar
Honoraria - Bayer Health (I); United medical (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (I); EMS; Exelixis (I); Lilly (I); United Health Group (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BMS Brazil (Inst); Exelixis (Inst); Lilly (I); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca